Do Analysts Agree Monday on Clovis Oncology Inc (CLVS) Stock's Target Price?
Monday, December 12, 2022 01:15 PM | InvestorsObserver Analysts
Mentioned in this article
InvestorsObserver is giving Clovis Oncology Inc (CLVS) an Analyst Rating Rank of 0, meaning CLVS is ranked higher by analysts than 0% of stocks. The average price target for CLVS is $2 and analyst’s rate the stock as a Sell.
Wall Street analysts are rating CLVS a Sell today. Find out what this means to you and get the rest of the rankings on CLVS!
You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers.
InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.
What's Happening With Clovis Oncology Inc Stock Today?
Clovis Oncology Inc (CLVS) stock is down -8.94% while the S&P 500 has gained 0.59% as of 1:14 PM on Monday, Dec 12. CLVS is lower by -$0.02 from the previous closing price of $0.20 on volume of 19,851,761 shares. Over the past year the S&P 500 is lower by -15.23% while CLVS is lower by -93.33%. CLVS lost -$1.82 per share the over the last 12 months.
Click Here to get the full Stock Report for Clovis Oncology Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
